PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Thursday reported a loss of $45.6 million in its fourth quarter.
The Pasadena, California-based company said it had a loss of 62 cents per share.
The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 83 cents per share.
The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $52.8 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $13.4 million.
For the year, the company reported a loss of $232.6 million, or $3.58 per share. Revenue was reported as $110.5 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.